Summary:
- Nutex Health (NUTX, Financial) posts impressive Q1 results, with GAAP EPS beating estimates by $1.68.
- Revenue surges 213.8% year-over-year, reaching $211.8 million.
- Adjusted EBITDA hits $72.8 million, marking a significant recovery.
Nutex Health (NUTX) delivered a robust performance in the first quarter, showcasing a GAAP EPS of $2.56, which significantly outpaced estimates by $1.68. The revenue saw a remarkable year-over-year increase of 213.8%, climbing to $211.8 million and surpassing expectations by $80.7 million. Furthermore, the company reported an adjusted EBITDA of $72.8 million, illustrating a significant turnaround from the previous year's loss.
Wall Street Analysts' Forecasts for Nutex Health
According to the one-year price targets provided by three analysts, Nutex Health Inc (NUTX, Financial) holds an average target price of $102.00. The high estimate is set at $150.00, while the low estimate stands at $56.00. The average price target suggests a potential downside of 19.00% from the current trading price of $125.93. For more in-depth estimate data, investors can visit the Nutex Health Inc (NUTX) Forecast page.
Brokerage Recommendations and GF Value Analysis
The consensus from three brokerage firms currently places Nutex Health Inc (NUTX, Financial) at an average brokerage recommendation of 2.0, signifying an "Outperform" status. This rating is part of a scale ranging from 1 to 5, where 1 represents a Strong Buy and 5 represents a Sell.
According to GuruFocus estimates, the projected GF Value for Nutex Health Inc (NUTX, Financial) in the next year is calculated to be $63.54. This assessment suggests a potential downside of 49.54% from the current price of $125.93. The GF Value is determined by considering the historical trading multiples of the stock, past business growth, and future business performance estimates. More comprehensive information can be accessed on the Nutex Health Inc (NUTX) Summary page.
